Kirin Holdings Company, Limited KNBWY
20.11 USD +1.08 (+5.68%)
At closeNov 5, 2026, 4:00 PM EST
19.50 Day range 20.12
14.31 52-week range 20.12
- YTD
- +33.53%
- 1 year
- +40.73%
- Market cap
- 15.90B
- EPS (ttm)
- 1.49
- P/E ratio
- 13.50
- YTD return
- +33.53%
- 1-year return
- +40.73%
- Volume
- 903
- Avg volume
- 23.06K
- Open
- 19.50
- Previous close
- 19.03
- Day's range
- 19.50 – 20.12
- 52-week range
- 14.31 – 20.12
- Earnings date
- Aug 6, 2026
1M +2.23 (+12.49%)
Next earnings
Aug 6, 2026
Expected Aug 6, 2026. Consensus EPS estimate 0.4792.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 6, 2026 | Jun 30, 2026 | 0.4792 | — | — | — |
| May 14, 2026 | Mar 31, 2026 | 0.26 | 0.21 | -0.05 | -19.23% |
| Feb 13, 2026 | Dec 31, 2025 | 0.4133 | 0.36 | -0.05 | -12.90% |
| Nov 11, 2025 | Sep 30, 2025 | 0.34 | 0.42 | +0.08 | +23.53% |
| Aug 7, 2025 | Jun 30, 2025 | 0.28 | 0.24 | -0.04 | -14.29% |
| May 13, 2025 | Mar 31, 2025 | 0.2126 | 0.20 | -0.01 | -5.93% |
News
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026 
Kirin (KNBWY) is an Incredible Growth Stock: 3 Reasons Why 
Are Investors Undervaluing Kirin (KNBWY) Right Now? 
Arcadia Biosciences (NASDAQ:RKDA) and Kirin (OTCMKTS:KNBWY) Financial Survey 
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH 
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML 
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL 
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML 
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress 
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Your note
Sign in to keep a note on KNBWY — it syncs with the Stock Master app.